Actinogen Medical is a biotech company providing treatments for Alzheimer’s disease and the cognitive decline associated with neurodegenerative and metabolic diseases. It develops Xanamem, a drug candidate designed to block the production of cortisol (the stress hormone) through the inhibition of the 11β-HSD1 enzyme in the brain.